4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Evogene Ltd. (EVGN) operates in the Biotechnology industry and is headquartered in Rehovot, Israel with about 52 employees. Its market capitalization is roughly $6 million. In the fiscal year ended 2025-12-31, EVGN reported $4M in revenue and ($8M) in net income.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications.
Interactive charts & full statements → Open the EVGN valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $4M | $6M | $3M | $2M |
| Gross Profit | ($0M) | $3M | $2M | $1M |
| Operating Income (EBIT) | ($14M) | ($19M) | ($22M) | ($27M) |
| Net Income | ($8M) | ($16M) | ($24M) | ($27M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $1M | $2M | $2M |
| Gross Profit | ($2M) | $0M | $1M | $1M | $1M |
| Operating Income (EBIT) | ($5M) | ($3M) | ($3M) | ($4M) | ($5M) |
| Net Income | ($5M) | $4M | ($4M) | ($3M) | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $20M | $40M | $51M | $56M | — |
| Total Liabilities | $8M | $25M | $22M | $21M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive EVGN viewer.
About TickerBase · Data methodology & sources